Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program.
Baldini E, Lunghi A, Cortesi E, Turci D, Signorelli D, Stati V, Melotti B, Ricciuti B, Frassoldati A, Romano G, Ceresoli GL, Illiano A, Verderame F, Fasola G, Ricevuto E, Marchetti P, Pinto C, Cartenì G, Scotti V, Tibaldi C, Fioretto L, Giannarelli D.
Baldini E, et al. Among authors: lunghi a.
Lung Cancer. 2020 Feb;140:59-64. doi: 10.1016/j.lungcan.2019.12.014. Epub 2019 Dec 20.
Lung Cancer. 2020.
PMID: 31881412